title: Characterization of Three CYP2C19 Gene Variants by MassARRAY and Point of Care Techniques: Experience from a Czech Centre.
abstract: Distribution of cytochrome P450 2C19 enzyme gene (CYP2C19) variants affecting metabolism of clopidogrel was determined in 526 Czech patients after percutaneous coronary intervention using MassARRAY genotyping and compared to distribution in other populations of European descent. Fifty-three (10%) patients underwent parallel determination of CYP2C19 genotypes from buccal swabs by a point of care technique with 100% concordance to the main genotyping platform. Observed CYP2C19 genotypes were related to clopidogrel metabolism phenotypes and discussed in population context. Hereby, presented methodologies provide accurate CYP2C19 genotyping results in a relatively short time of one up to 12 h and may, therefore, find the relevant place in the field of genotype-guided antiplatelet therapy.
authors.affiliation: Laboratory of Cardiogenomics-LEM, University Hospital Olomouc, Olomouc, Czech Republic. martin.petrek@fnol.cz.|Faculty of Medicine and Dentistry, Institute of Molecular and Translational Medicine, Palacký University Olomouc, Olomouc, Czech Republic. martin.petrek@fnol.cz.|Department of Pathological Physiology, Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic. martin.petrek@fnol.cz.
authors.forename: Martin
authors.identifier: http://orcid.org/0000-0002-4517-7825
authors.initials: M
authors.lastname: Petrek
authors.affiliation: Laboratory of Cardiogenomics-LEM, University Hospital Olomouc, Olomouc, Czech Republic.|Department of Pathological Physiology, Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic.
authors.forename: Lenka
authors.initials: L
authors.lastname: Kocourkova
authors.affiliation: Laboratory of Cardiogenomics-LEM, University Hospital Olomouc, Olomouc, Czech Republic.|Department of Pathological Physiology, Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic.
authors.forename: Veronika
authors.initials: V
authors.lastname: Zizkova
authors.affiliation: Department of Pathological Physiology, Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic.
authors.forename: Zdenek
authors.initials: Z
authors.lastname: Nosek
authors.affiliation: Department of Internal Medicine-Cardiology, Faculty of Medicine and Dentistry, Palacký University and University Hospital Olomouc, Olomouc, Czech Republic.
authors.forename: Milos
authors.initials: M
authors.lastname: Taborsky
authors.affiliation: Department of Pathological Physiology, Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic. jana.petrkova@fnol.cz.|Department of Internal Medicine-Cardiology, Faculty of Medicine and Dentistry, Palacký University and University Hospital Olomouc, Olomouc, Czech Republic. jana.petrkova@fnol.cz.
authors.forename: Jana
authors.initials: J
authors.lastname: Petrkova
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000077144:Clopidogrel; D065731:Cytochrome P-450 CYP2C19 / Q000235:genetics*; D018153:Czech Republic; D005260:Female; D014644:Genetic Variation; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D020411:Oligonucleotide Array Sequence Analysis; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects; D010597:Pharmacogenetics; D010641:Phenotype; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D019095:Point-of-Care Systems; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D013988:Ticlopidine
keywords: CYP2C19; Clopidogrel; Genotyping; Pharmacogenetics; Point of care